Results 71 to 80 of about 35,587 (246)

Discovery of novel IDH1-R132C inhibitors through structure-based virtual screening

open access: yesFrontiers in Pharmacology, 2022
Isocitrate dehydrogenase (IDH) belongs to a family of enzymes involved in glycometabolism. It is found in many living organisms and is one of the most mutated metabolic enzymes.
Chujiao Hu   +16 more
doaj   +1 more source

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. Methods This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with ...
Tali Eviatar   +35 more
wiley   +1 more source

Correlation of microRNAs-10b/21/34a expression levels with IDH1-mutation status in patients with glioblastoma [PDF]

open access: yesSrpski Arhiv za Celokupno Lekarstvo
Introduction/Objective. Isocitrate dehydrogenase (IDH) mutations play a significant role in gliomagenesis. Specific microRNAs, such as microRNA-10b and microRNA-21, act as oncogenic microRNAs, whereas microRNA-34a acts as a tumor suppressor in ...
Stepanović Aleksandar   +3 more
doaj   +1 more source

The emerging role of Nrf2 in heart failure: From cardioprotection to therapeutic approaches

open access: yesESC Heart Failure, EarlyView.
Nrf2 signalling is impaired in heart failure, contributing to oxidative stress, mitochondrial dysfunction, and ferroptosis, which drive neurohormonal activation, inflammation, and ischaemia‐reperfusion injury. This loss of Nrf2 activity exacerbates hypertension, diabetic cardiomyopathy, and cardiotoxicity, accelerating progression to overt heart ...
Emiliano Fiori   +9 more
wiley   +1 more source

Supplementary figure-2 from Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma [PDF]

open access: gold, 2023
Joydeep Mukherjee   +6 more
openalex   +1 more source

Epigenotoxicity: Decoding the epigenetic imprints of genotoxic agents and their implications for regulatory genetic toxicology

open access: yesEnvironmental and Molecular Mutagenesis, EarlyView.
Abstract Regulatory genetic toxicology focuses on DNA damage and subsequent gene mutations. However, genotoxic agents can also affect epigenetic marks, and incorporation of epigenetic data into the regulatory framework may thus enhance the accuracy of risk assessment.
Roger Godschalk   +4 more
wiley   +1 more source

IDH1andIDH2Mutations in Gliomas [PDF]

open access: yesNew England Journal of Medicine, 2009
A recent genomewide mutational analysis of glioblastomas (World Health Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate dehydrogenase 1 gene (IDH1) in a fraction of such tumors, most frequently in tumors that were known to have evolved from lower-grade gliomas (secondary glioblastomas).We determined the sequence of the ...
Yan, Hai   +17 more
openaire   +3 more sources

Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia

open access: yesHaematologica, 2019
Persistence of IDH1 or IDH2 mutations in remission bone marrow specimens of patients with acute myeloid leukemia has been observed, but the clinical impact of these mutations is not well known.
Chi Young Ok   +17 more
doaj   +1 more source

IDH1/2 Mutants Inhibit TET-Promoted Oxidation of RNA 5mC to 5hmC. [PDF]

open access: yesPLoS ONE, 2016
TETs (TET1/2/3) play critical roles in multi cellular processes through DNA demethylation driven by oxidation of DNA 5mdC to 5hmdC. Interestingly, recent studies indicated that TETs also oxidate RNA 5mC to 5hmC.
Qiang Xu   +6 more
doaj   +1 more source

Bridging the Gap: How Organ‐on‐a‐Chip Technology Facilitates the Battle against Glioma

open access: yesSmall Science, EarlyView.
This review critically evaluates current state‐of‐the‐art in vitro glioma models especially glioma‐on‐a‐chip models based on readout capability, performance, and physiological relevance. It summarizes the key parameters and proposes a practical framework to guide researchers in selecting the most suitable preclinical models for glioma studies.
Su Liu   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy